WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H200185
CAS#: 1002304-34-8
Description: AMG 208 is a selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 208 inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity, which may result in cell growth inhibition in tumors that overexpress c-Met. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase, plays an important role in epithelial cell proliferation and has been shown to be overexpressed in a variety of cancers.
Hodoodo Cat#: H200185
Name: AMG208
CAS#: 1002304-34-8
Chemical Formula: C22H17N5O2
Exact Mass: 383.14
Molecular Weight: 383.400
Elemental Analysis: C, 68.92; H, 4.47; N, 18.27; O, 8.35
Synonym: AMG208; AMG 208; AMG-208.
IUPAC/Chemical Name: 4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]-7-methoxyquinoline
InChi Key: HEAIZQNMNCHNFD-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H17N5O2/c1-28-16-7-8-17-19(13-16)23-12-11-20(17)29-14-22-25-24-21-10-9-18(26-27(21)22)15-5-3-2-4-6-15/h2-13H,14H2,1H3
SMILES Code: COC1=CC=C2C(OCC3=NN=C4C=CC(C5=CC=CC=C5)=NN43)=CC=NC2=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: AMG-208 is currently developed and investigated by Amgen as an anticancer drug candidate. Amgen-208 inhibits both ligand-dependent and ligand-independent c-Met activation. As of 2010, Amgen is in phase 1 clinical trials. (source: http://clinicaltrials.gov/ct2/show/NCT00813384).
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 383.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |